IMPLANET Announces the European Launch of the MIS Range, a Minimally Invasive Pedicle Screw System
June 21 2023 - 11:00AM
Business Wire
- First innovation resulting from the partnership with Sanyou
Medical
- First orders received in June 2023
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME equity savings plans), a medical technology company
specializing in implants for orthopedic surgery and the
distribution of technological medical equipment, today announced
the launch of the MIS range, a minimally invasive pedicle screw
positioning system, a result of joint developments with its partner
Sanyou Medical.
Ludovic Lastennet, Implanet’s CEO, commented: “With the
launch of this range of minimally invasive pedicle screws, we are
reaffirming our ability to innovate by developing products that
provide a response to both surgeons’ requirements and their
patients’ pathologies, thus significantly reducing the trauma open
surgery can cause. This first innovation in partnership with Sanyou
Medical also illustrates the strength of this alliance concluded at
the end of 2022 with one of China’s foremost manufacturers of
medical devices. We have been able to swiftly share our respective
expertise to develop this first range, which supplements and
strengthens our positioning in the treatment of adult spine
disorders”.
Minimally invasive spine surgery was developed to treat spinal
pathologies while limiting tissue damage, Bleeding, and post
operative infection, with the goal of faster recovery.
The pedicle screw system proposed by Implanet consists of latest
generation implants and a single set of instruments. The range of
pedicle screws and associated implants provides surgeons with a
comprehensive solution for treating degenerative, traumatic or
tumoral spine pathologies.
Within the framework of this European commercial launch,
Implanet has initiated system demonstrations in various health
centers in Europe and has already received its first orders in June
2023.
Cash position
At May 31, 2023, Implanet had a cash position of €1.51
million.
As a reminder, the payment of the balance of the MADISONTM
business, totaling €2.30 million, is spread over time depending on
the achievement of certain regulatory milestones relating to CE
marking, with €1.45 million of this figure received as expected
during the second quarter of 2023.
Given these elements, combined with short-term actions to
optimize cash flow, the Company considers that it has the means to
cover its expected business financing requirements through to the
end of 2023.
The Company is actively studying several financing solutions in
order to support the commercial development of its medical
devices.
Upcoming financial events:
- H1 2023 revenue, July 11, 2023,
after market - H1 2023 results, September 19, 2023, after
market
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that
manufactures high-quality implants for orthopedic surgery and
distributing medical technology equipment. Its activity revolves
around a comprehensive innovative solution for improving the
treatment of spinal pathologies (JAZZ®) complemented by the product
range offered by Orthopaedic & Spine Development (OSD),
acquired in May 2021 (thoraco-lumbar screws, cages and cervical
plates). Implanet’s tried-and-tested orthopedic platform is based
on the traceability of its products. Protected by four families of
international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States, the CE mark in Europe and ANVISA approval in Brazil. In
2022, IMPLANET entered into a commercial, technological and
financial partnership with SANYOU MEDICAL, China's second largest
medical device manufacturer. IMPLANET employs 43 staff and recorded
a consolidated revenue of €8.0 million in 2022. Based near Bordeaux
in France, IMPLANET opened a US subsidiary in Boston in 2013.
IMPLANET is listed on the Euronext Growth market in Paris. For
further information, please visit www.Implanet.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621944217/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
NewCap Media Relations Arthur Rouillé Tél.: +33 (0)1 44
71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Historical Stock Chart
From Apr 2024 to May 2024
Implanet (EU:ALIMP)
Historical Stock Chart
From May 2023 to May 2024